Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension

The efficacy and safety of azilsartan medoxomil (AZL‐M) were evaluated in African‐American patients with hypertension in a 6‐week, double‐blind, randomized, placebo‐controlled trial, for which the primary end point was change from baseline in 24‐hour mean systolic blood pressure (BP). There were 413...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Hypertens (Greenwich)
Autors principals: Johnson, Wallace, White, William B., Sica, Domenic, Bakris, George L., Weber, Michael A., Handley, Alison, Perez, Alfonso, Cao, Charlie, Kupfer, Stuart, Saunders, Elijah B.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Hypertension Therapy
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8031359/
https://ncbi.nlm.nih.gov/pubmed/28493376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jch.12993
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars